Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TYK Medicines, Inc. Class H ( (HK:2410) ) just unveiled an update.
TYK Medicines said its investigational Class 1 new drug Asandeutertinib (TY-9591) has been proposed by China’s Center for Drug Evaluation to be included in the national priority review list for first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer, including central nervous system metastases, carrying specific EGFR mutations, underscoring the potential strategic importance of this candidate in the competitive lung cancer therapy market. The board also addressed recent unusual share price and trading volume movements, stating it is unaware of any undisclosed information behind the volatility, and confirmed that the group’s business operations remain normal and stable with core projects progressing as planned, while cautioning investors that there is no assurance the drug will ultimately be successfully developed and marketed.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong, focused on the research and development of innovative Class 1 new drugs, with an emphasis on oncology treatments for conditions such as non-small cell lung cancer.
Average Trading Volume: 3,443,116
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.85B
Learn more about 2410 stock on TipRanks’ Stock Analysis page.